Abstract

BackgroundXL092 is a novel, oral inhibitor of multiple receptor tyrosine kinases including MET, VEGFR2, AXL, and MER, which are implicated in tumor growth, metastasis, angiogenesis, and immune modulation. XL092 has...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call